UCB SA (OTCMKTS:UCBJY – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 7,614 shares, a drop of 63.8% from the October 15th total of 21,017 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 76,592 shares, the days-to-cover ratio is currently 0.1 days.
UCB Stock Performance
Shares of UCBJY stock opened at $163.75 on Monday. UCB has a 1 year low of $110.55 and a 1 year high of $168.76. The stock’s 50 day simple moving average is $131.08 and its two-hundred day simple moving average is $140.66.
Analysts Set New Price Targets
Several research firms recently weighed in on UCBJY. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 27th. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.
View Our Latest Research Report on UCB
About UCB
UCB is a Belgian biopharmaceutical company headquartered in Brussels. Founded in 1928, it develops medicines for people with serious neurological and immune-mediated diseases, with research focused on areas such as epilepsy and inflammatory conditions. Its products include epilepsy treatments such as Briviact and Vimpat, as well as medicines for immune-mediated diseases, including Bimzelx and Cimzia. Product availability and approved uses vary by country. UCB serves patients and healthcare providers across international markets through its global operations.
Further Reading
- Five stocks we like better than UCB
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
